目的 探讨苏黄止咳胶囊联合卡介菌多糖核酸注射液治疗咳嗽变异性哮喘临床疗效观。方法 选取2017年8月—2018年8月在天津市泰达医院治疗的咳嗽变异性哮喘患者88例，随机为对照组（44例）和治疗组（44例）。对照组肌肉注射卡介菌多糖核酸注射液，1 mL/次，2次/周；治疗组在对照组基础上口服苏黄止咳胶囊，3粒/次，3次/d。两组患者均治疗8周。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状评分、肺功能、血清学指标和LCQ量表评分。结果 治疗后，对照组临床有效率为81.82%，显著低于治疗组的97.73%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者症状积分均明显降低（P<0.05），且治疗组症状积分明显低于对照组（P<0.05）。治疗后，两组患者第一秒用力呼气容积（FEV1）、用力肺活量（FVC）、呼气峰流速（PEF）均明显升高（P<0.05），且治疗组患者肺功能明显好于对照组（P<0.05）。治疗后，两组患者血清IL-4、IL-6、金属蛋白酶抑制因子1（TIMP-1）、降钙素原（PCT）水平均显著降低（P<0.05），IL-2、IL-10和IFN-γ水平显著升高（P<0.05），且治疗组患者上述血清学指标明显好于对照组（P<0.05）。治疗后，两组LCQ量表各项目评分均明显升高（P<0.05），且治疗组患者LCQ量表各评分明显高于对照组（P<0.05）。结论 苏黄止咳胶囊联合卡介菌多糖核酸注射液治疗咳嗽变异性哮喘可有效改善患者临床症状，降低机体炎症因子水平，同时也可显著提升患者生活质量水平。

Objective To explore the clinical efficacy of Suhuang Zhike Capsules combined with BCG polysaccharide nucleic acid in treatment of cough variant asthma. Methods Patients (88 cases) with cough variant asthma in Tianjin TEDA Hospital from August 2017 to August 2018 were randomly divided into control (44 cases) and treatment (44 cases) groups. Patients in the control group were im administered with BCG Polysaccharide and Nucleic Acid Injection, 1 mL/time, twice weekly. Patients in the treatment group were po administered with Suhuang Zhike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, pulmonary function, serological indicators and LCQ scale score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.82%, which was significantly lower than 97.73% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the clinical symptom scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the FEV1, FVC, and PEF levels in two groups were significantly increased (P<0.05), and the pulmonary function in the treatment group were significantly better than that in the control group (P<0.05). After treatment, the serum IL-4, IL-6, TIMP-1, and PET levels in two groups were significantly decreased, but IL-2, IL-10, and IFN-γ levels in two groups were significantly increased (P<0.05), and these factors in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the LCQ scale scores in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Suhuang Zhike Capsules combined with BCG polysaccharide nucleic acid in treatment of cough variant asthma can effectively improve the clinical symptoms, reduce the level of inflammatory factors, and improve the quality of life.